Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONNECT study of Tecfidera in pediatric relapsing-remitting multiple sclerosis
2023-505632-35-00Phase 3Completed
- Sponsor
- Biogen
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of dimethyl fumarate in relapsing-remitting multiple sclerosis (RRMS) (3 arms), sponsored by Biogen. Started Oct 2024; status: completed.
02
Drugs
dimethyl fumarate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2023-505632-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505632-35-00.